Related Experiment Video
Updated: Jun 17, 2026
06:07
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
MT1G hypermethylation: a potential prognostic marker for hepatoblastoma
Luis H T Sakamoto1, Beatriz DE Camargo, Mariana Cajaiba
1Ludwig Institute for Cancer Research, São Paulo Branch, São Paulo 01323-903, Brazil.
Pediatric Research
|December 25, 2009
Summary
Aberrant DNA hypermethylation is frequent in hepatoblastoma, a rare childhood cancer. Promoter hypermethylation of the MT1G gene correlates with poor prognosis, suggesting its use as a prognostic indicator.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Hepatoblastoma is a rare childhood cancer (1% of pediatric cancers) with limited known prognostic factors, often related to resectability.
- Microarray studies indicate widespread gene underexpression in hepatoblastoma, suggesting epigenetic mechanisms like DNA methylation may contribute to tumor suppressor gene inactivation.
Purpose of the Study:
- To quantitatively evaluate the promoter methylation patterns of 25 genes in hepatoblastoma.
- To investigate the association between DNA methylation and hepatoblastoma prognosis.
Main Methods:
- Quantitative methylation-specific PCR (QMSP) was used to analyze the methylation status of 25 genes in 20 hepatoblastoma tumor specimens and 5 normal liver samples.
- Tumor-specific DNA hypermethylation was assessed in promoter regions.
Main Results:
- A high frequency of tumor-specific DNA hypermethylation was observed in the promoter regions of five genes: APC, CDH1, MT1G, RASSF1A, and SOCS1.
- Hypermethylation of the MT1G gene showed a significant correlation with a poor prognosis in hepatoblastoma patients.
Conclusions:
- Aberrant promoter hypermethylation is a common event in hepatoblastoma, representing a significant molecular feature of this malignancy.
- MT1G hypermethylation may serve as a valuable prognostic biomarker for hepatoblastoma.
- These findings suggest potential therapeutic strategies involving demethylating agents for hepatoblastoma patients.
